BiomX
Financing Rounds
- Public
- Exit
Round Led by Symbiosis
Round Led by Symbiosis
BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
View Website
Modality
- Biologic
Indications
- Circulatory & Metabolic Disease
- Dermatology
Development Status
- Phase 1